Innovative Pharmaceutical Biotech Limited Stock price

Equities

399

BMG4783W1073

Industrial Machinery & Equipment

Market Closed - Hong Kong S.E. 04:08:03 2024-03-28 am EDT 5-day change 1st Jan Change
0.2 HKD -0.99% Intraday chart for Innovative Pharmaceutical Biotech Limited -0.50% -8.68%
Sales 2022 11.14M 1.42M Sales 2023 8.07M 1.03M Capitalization 305M 38.93M
Net income 2022 45M 5.75M Net income 2023 -246M -31.44M EV / Sales 2022 108 x
Net Debt 2022 984M 126M Net Debt 2023 1.24B 158M EV / Sales 2023 191 x
P/E ratio 2022
-4.15 x
P/E ratio 2023
-1.24 x
Employees 20
Yield 2022 *
-
Yield 2023
-
Free-Float 46.67%
More Fundamentals * Assessed data
Dynamic Chart
Innovative Pharmaceutical Biotech Returns to Fiscal H1 Attributable Profit MT
Innovative Pharmaceutical Biotech Limited Reports Earnings Results for the Half Year Ended September 30, 2023 CI
Innovative Pharmaceutical Biotech to Return to Profit in Fiscal H1 MT
Innovative Pharmaceutical Biotech Limited Provides Unaudited Earnings Guidance for the Six Months Ended 30 September 2023 CI
Innovative Pharmaceutical Biotech Limited Announces Change of Address of Principal Place of Business in Hong Kong CI
Innovative Pharmaceutical Eyes Majority Stake in US Neurotechnology Firm MT
Innovative Pharmaceutical Biotech Limited entered into a memorandum of understanding to acquire a majority interest in Niraxx Light Therapeutics, Inc. CI
Innovative Pharmaceutical Plans HK$55.5 Million Bond Issue MT
Innovative Pharmaceutical to Raise HK$58 Million From Deal with US Firm Genuine Marketing MT
Innovative Pharmaceutical Biotech Limited announced that it expects to receive HKD 55.5 million in funding CI
Innovative Pharmaceutical Biotech Limited Appoints Cheng Tak Yiu as an Executive Director CI
Innovative Pharmaceutical Biotech Incurs Loss in Fiscal Year 2023 MT
Innovative Pharmaceutical Biotech Limited Reports Earnings Results for the Full Year Ended March 31, 2023 CI
Innovative Pharmaceutical Biotech Mulls Over Capital Injection in Technical Services Company MT
Innovative Pharmaceutical Biotech Limited Reports Earnings Results for the Half Year Ended September 30, 2022 CI
More news
1 day-0.99%
1 week-0.50%
Current month-2.44%
1 month-1.96%
3 months-1.96%
6 months-14.16%
Current year-8.68%
More quotes
1 week
0.19
Extreme 0.192
0.20
1 month
0.19
Extreme 0.192
0.21
Current year
0.19
Extreme 0.19
0.23
1 year
0.19
Extreme 0.19
0.37
3 years
0.11
Extreme 0.112
0.37
5 years
0.11
Extreme 0.112
0.42
10 years
0.11
Extreme 0.112
1.60
More quotes
Managers TitleAgeSince
Chief Tech/Sci/R&D Officer 72 10-08-31
Comptroller/Controller/Auditor 58 13-05-13
Members of the board TitleAgeSince
Director/Board Member 50 23-07-03
Director/Board Member 69 16-01-03
Director/Board Member 66 09-11-05
More insiders
Date Price Change Volume
24-03-28 0.2 -0.99% 100
24-03-27 0.202 +1.00% 87,000
24-03-26 0.2 0.00% 110,000
24-03-25 0.2 -0.50% 78,500
24-03-22 0.201 0.00% 0

Delayed Quote Hong Kong S.E., March 28, 2024 at 04:08 am EDT

More quotes
Innovative Pharmaceutical Biotech Limited is a Hong Kong-based investment holding company principally engaged in pharmaceuticals and biotechnology businesses. The Company operates through five segments. Genetic Testing Services segment is engaged in the provision of genetic testing services in the People's Republic of China (PRC) and Hong Kong. Bio-Industrial Products segment is engaged in the distribution of bio-industrial products in the PRC. Beauty Equipment and Products segment is engaged in the trading of beauty equipment and products in Hong Kong. Securities Investment segment is engaged in securities investment in Hong Kong and outside Hong Kong. Research and Development segment is engaged in the research, development and commercialization of the oral insulin products.
More about the company

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Innovative Pharmaceutical Biotech Limited - Hong Kong S.E.